



# THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Transcriptional regulation and macrophage differentiation

**Citation for published version:**

Hume, D, Summers, K & Rehli, M 2016, 'Transcriptional regulation and macrophage differentiation', *Microbiology Spectrum*, vol. 4, no. 3, MCHD-0024-2015. <https://doi.org/10.1128/microbiolspec.MCHD-0024-2015>

**Digital Object Identifier (DOI):**

[10.1128/microbiolspec.MCHD-0024-2015](https://doi.org/10.1128/microbiolspec.MCHD-0024-2015)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

Microbiology Spectrum

**Publisher Rights Statement:**

"Copyright © American Society for Microbiology, Microbiology Spectrum [insert citation]" for the HTML version).

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# Transcriptional Regulation and Macrophage Differentiation

DAVID A. HUME,<sup>1</sup> KIM M. SUMMERS,<sup>1</sup> and MICHAEL REHLI<sup>2</sup>

<sup>1</sup>University of Edinburgh, The Roslin Institute and Royal (Dick) School of Veterinary Studies, Midlothian EH25 9RG, United Kingdom; <sup>2</sup>University Hospital Regensburg, Department of Internal Medicine III, D-93047 Regensburg, Germany

**ABSTRACT** Monocytes and macrophages are professional phagocytes that occupy specific niches in every tissue of the body. Their survival, proliferation, and differentiation are controlled by signals from the macrophage colony-stimulating factor receptor (CSF-1R) and its two ligands, CSF-1 and interleukin-34. In this review, we address the developmental and transcriptional relationships between hematopoietic progenitor cells, blood monocytes, and tissue macrophages as well as the distinctions from dendritic cells. A huge repertoire of receptors allows monocytes, tissue-resident macrophages, or pathology-associated macrophages to adapt to specific microenvironments. These processes create a broad spectrum of macrophages with different functions and individual effector capacities. The production of large transcriptomic data sets in mouse, human, and other species provides new insights into the mechanisms that underlie macrophage functional plasticity.

## THE CELLS OF THE MONONUCLEAR PHAGOCYTE SYSTEM

The mononuclear phagocyte system (MPS) was originally defined by van Furth and Cohn (1) as a family of cells of the innate immune system derived from hematopoietic progenitor cells under the influence of specific growth factors (2, 3). Differentiated cells of the MPS, monocytes and macrophages, are effectors of innate immunity, engulfing and killing pathogens. They are also needed for tissue repair and resolution of inflammation and for the generation of an appropriate acquired immune response. Their biology and differentiation have been reviewed by a number of authors (2, 4–8). The original definition of the MPS considered an essentially linear sequence from pluripotent progenitors, through committed myeloid progenitors shared with granulocytes, to promonocytes and blood monocytes, and thence

to tissue macrophages (2, 4–8). Resident macrophages differ in function between tissues, and within tissues they occupy a specific niche (9). In some locations, for example, associated with epithelia, they clearly have individual identifiable territories that form a regular pattern (2, 3).

## THE BIOLOGY OF BLOOD MONOCYTE SUBSETS

Monocytes in peripheral blood have been subdivided into subsets based on certain surface markers (4, 9–13). The seminal study in the area of monocyte subset function (14) segregated mouse peripheral blood monocytes based on their expression of chemokine receptors and behavior on adoptive transfer; those expressing CCR2 (and the marker Ly6C) were recruited to inflammatory sites, whereas those expressing CX3CR1 were selectively recruited to noninflammatory sites. Subsequent mouse studies have indicated that Ly6C<sup>hi</sup> monocytes replenish the large resident macrophage population of the gastrointestinal tract (15–18) and patrol the extravascular space in many other organs (19). The more mature Ly6C<sup>lo</sup> populations, which have a much longer half-life in the circulation, may perform a patrolling

**Received:** 14 October 2015, **Accepted:** 23 October 2015, **Published:** 3 June 2016

**Editor:** Siamon Gordon, Oxford University, Oxford, United Kingdom

**Citation:** Hume DA, Summers KM, Rehl M. 2016. Transcriptional regulation and macrophage differentiation. *Microbiol Spectrum* 4(3): MCHD-0024-2015. doi:10.1128/microbiolspec.MCHD-0024-2015.

**Correspondence:** David A. Hume, david.hume@roslin.ed.ac.uk  
© 2016 American Society for Microbiology. All rights reserved.

function in the circulation and sense nucleic acids and viruses (16, 20, 21). The subsets have also been referred to as “classical” (Ly6C<sup>hi</sup> in mice or CD14<sup>hi</sup> in humans) and “nonclassical” (Ly6C<sup>lo</sup> in mice or CD16<sup>hi</sup> in humans) under a proposed unifying nomenclature (11, 13). Given the lack of correlation between markers, and species differences, it is likely that these populations could be further subdivided into different and/or smaller subsets using additional markers. Rather than give the subsets names, it may be better to refer specifically to the markers used. Expression array profiling of human and mouse monocyte subsets defined by the markers described above (Ly6C and CD14/16) supported the idea that these subsets were functionally equivalent across species, although there were many species-specific expression differences (22). One major difference between mice and humans is the relative abundance of the subsets. In mice, the major populations are equally abundant, whereas in humans, the CD16<sup>hi</sup> subset is a minor subpopulation that also varies widely with disease states. CD16 as a marker is also difficult to interpret since there is extensive copy number variation in the gene encoding this marker, *FCG3RB*, underlying inflammatory disease susceptibility in humans (23). In humans, an “intermediate” population (CD14<sup>int</sup>, CD16<sup>int</sup>) has been identified and attributed specialized functions (10–13). As discussed further below, the definition of the intermediate population depends somewhat on the position of gates on the fluorescence-activated cell sorter, and the use of other markers such as SLAN and TIE2 may produce distinct subsets (10, 12). Bovine monocytes have also been subdivided based on CD14 and CD16 as markers, with CD172a (*SIRPA*) and CD163 providing additional markers that varied between subpopulations (24). Pig peripheral blood monocytes, which were more human-like than were mouse macrophages in their overall gene expression profiles, could also be subdivided into roughly equal subsets, depending on reciprocal expression of CD14 and CD163, but appeared to lack a genuine “nonclassical” population (25). In rats, a separate marker, CD43, separates monocytes into two populations (26). As in the mouse, these populations differ in their expression of chemokine receptors CCR2 and CX3CR1 (26). CD43 expression also differs between the mouse monocyte subpopulations (27). Adoptive transfer and lineage trace studies in the mouse and rat confirmed that the mature (Ly6<sup>lo</sup>CD43<sup>hi</sup>) cells derive from the Ly6C<sup>hi</sup>CD43<sup>lo</sup> cells (26, 28, 29). The monocyte subpopulations are therefore likely to be the extremes of a differentiation series, in which the time spent in transition is relatively short.

## THE DEVELOPMENT OF THE MPS

During embryonic development in the mouse, macrophages are first identifiable as a distinct cell type in the yolk sac, and from that location they migrate and infiltrate all of the tissues of the body. In mice, the first appearance occurs in Reichert’s membrane (30). The yolk sac-derived macrophages are apparently generated as mature macrophages, without an obvious monocyte-like intermediate, and are highly motile, actively phagocytic, and proliferative (31–33). In outbred mice, these yolk sac-derived macrophages lacked detectable expression of the macrophage-specific transcription factor PU.1, and the null mutation of the *Spi1* gene encoding PU.1 did not compromise their development (32, 33). Subsequent studies demonstrated that the impact of the *Spi1* knockout mutation depends strongly on genetic background; in some strains the knockout is mid-gestation lethal, whereas in others it is myelodeficient at birth (34). The initial view, based on studies in the chick, was that yolk sac-derived macrophages are replaced later in development by the products of definitive hematopoiesis (35). This view was strongly supported by recent cellular transplantation studies in the chicken, where yolk sac cells injected into early embryos produced macrophages that were lost by the time of hatch, but bone marrow-derived cells produced long-term chimerism (36). Unexpectedly, this chimerism was restricted to the macrophage lineage, suggesting the existence of a macrophage-restricted progenitor cell in the bone marrow that has self-renewal capacity. There is also some evidence for such a progenitor in the mouse (37–39).

In the mouse, an emerging consensus is that populations of tissue macrophages, notably the microglia of the brain (40), the epidermal macrophages (Langerhans cells) of the skin (41, 42), and alveolar macrophages of the lung (43), are seeded from the yolk sac or fetal liver during development, and thereafter are maintained by self-renewal (reviewed in reference 38). However, this consensus depends on assumptions about the validity of the models used. Almost all of these studies use a single inbred mouse strain, C57BL/6, because most knockouts and conditional reporters have been made on this background. By contrast to the outbred mice, in the C57BL/6 line yolk sac macrophages were apparently dependent on PU.1, which was expressed in the yolk sac, and were independent of the expression of c-MYB, which is expressed in definitive hematopoietic stem cells (HSCs) (44). The view that the yolk sac is a major source of tissue macrophages in the adult has been extended to the point where blood monocytes are no longer believed

to make a significant contribution to any tissue macrophage population (29, 44, 45) other than that of the gastrointestinal tract (46). The vast majority of adult tissue-resident macrophages in adult mouse liver, brain, skin, and lung were proposed to originate from yolk sac erythromyeloid progenitors, distinct from HSCs that colonize the fetal liver, with minimal replacement from HSC progeny (via blood monocytes) even by 1 year of age (47, 48).

Other authors, using different experimental models, have reached a different conclusion about the role of the yolk sac and embryonic macrophages in adult macrophage populations. Epelman et al. (49) reported that ~50% of macrophages in most organs, other than brain, were labeled with a conditional reporter driven by the *Flt3* promoter, which is expressed in HSCs. Neither *Flt3* mRNA nor the conditional reporter was detected in the yolk sac, and they were relatively low even in fetal liver. Sheng et al. (50), using a conditional reporter gene based on the *Kit* locus, which is expressed only in HSCs, also concluded that the large majority of tissue macrophages derive from definitive progenitors. On the basis of these data, one would conclude that definitive marrow-derived macrophages gradually replace those of embryonic origin. The most recent contribution to this emerging field made the interesting observation that the yolk sac-derived macrophages could be ablated with injection of antibody to macrophage colony-stimulating factor receptor (CSF-1R) into the embryo, and they were apparently replaced by distinct c-MYB-dependent fetal liver-derived monocytes by the end of gestation (51). These authors used inducible lineage trace markers to support the view that the large majority of tissue macrophages are derived from fetal liver-derived monocytes that seed tissue in the embryo and then self-renew. They reiterate the view that microglia are derived exclusively from the yolk sac macrophage population. However, in mice treated with anti-CSF-1R the microglia were repopulated, presumably from the monocytic source, by the time of birth. This finding may relate to much earlier observations, using outbred mice, that monocytes entered the brain, and especially the retina, and clearly transdifferentiated into microglia, around the time of birth (52, 53).

## HOMEOSTASIS AND THE MACROPHAGE NICHE

As noted above, the distribution of macrophages in tissues is very regular; individual cells occupy a specific niche and seldom overlap processes with each other.

Each of the models used to infer the origins and turnover of tissue macrophages in mice makes the assumption that the methods used do not disturb the steady state, and this assumption may also not be valid. The proliferation and differentiation of macrophages is controlled by CSF-1R, which is activated by two ligands, macrophage colony-stimulating factor (CSF-1) and interleukin-34 (IL-34) (7, 54). Administration of CSF-1 to mice promoted expansion of the monocyte pool and increased monocyte infiltration into tissues and tissue-resident macrophage proliferation (55–57). CSF-1 is cleared from the circulation through receptor-mediated endocytosis by the CSF-1 receptor, involving both the macrophages of the liver and spleen (58) and blood monocytes (29). Accordingly, blockade of the CSF-1R with a monoclonal antibody causes a massive increase in circulating CSF-1 (59). The central role of CSF-1 in macrophage homeostasis is evident from the CSF-1-deficient osteopetrotic (*Csf1<sup>op/op</sup>*) mouse and toothless rat (*Csf1<sup>tl/tl</sup>*), which have gross deficiencies of tissue macrophages and many pleiotropic consequences of that deficiency (60). Treatment with anti-CSF-1R antibody also depletes most tissue macrophage populations in adult mice, indicating that CSF-1 dependence is maintained throughout life. Anti-CSF-1R does not deplete monocytes (59), nor does it impact on monocytopoiesis (61), but it does prevent differentiation to form the Ly6C<sup>lo</sup> population (29, 59).

Based on the available data, there is an intrinsic CSF-1/CSF-1R feedback loop that controls monocyte numbers and differentiation, monocyte recruitment, and tissue macrophage numbers through the local and systemic availability of CSF-1. When an individual macrophage niche becomes vacant, CSF-1 is no longer consumed and the local CSF-1 concentration rises to promote either local proliferation or recruitment of blood monocytes. Studies of development and turnover of mononuclear phagocytes need to take account of this homeostatic loop. Inducible Cre reporters, bone marrow transplantation, parabiosis, and monocyte depletion/mutations are all very likely to alter the homeostatic balance by altering the availability of CSF-1 (17). For example, the estrogen analog tamoxifen is commonly used in lineage trace experiments. There is evidence that CSF-1 expression is regulated by estrogen and is elevated in ovariectomized mice and in pregnancy (62, 63). Furthermore, hematopoietic progenitor cells respond directly to estrogen, which modulates their differentiation in the presence of myeloid growth factors (64). When embryos are pulsed with tamoxifen to induce recombinase activity, the same treatment may induce or repress CSF-1 in the embryo or

the mother and alter the relative contribution of yolk sac phagocytes. Once a macrophage niche has been occupied by a yolk sac-derived progenitor, it may be less available to cells of definitive origin. Similarly, the lack of any impact on tissue macrophage numbers when monocytes are depleted (for example, in MYB or CCR2 knockout mice) could be explained by the increased availability of circulating CSF-1 (29), leading to the compensatory proliferation of the tissue-resident macrophages.

## TRANSCRIPTOMIC ANALYSIS OF THE RELATIONSHIP BETWEEN MACROPHAGES AND DENDRITIC CELLS

The functional definition of a macrophage is in the name, “big eater,” coined by Elie Metchnikoff (65). One might expect that the set of genes required to make up a professional phagocyte would be coexpressed in macrophages, and this might also provide clues to the function of genes for which there is poor annotation. The principle of guilt by association has been confirmed many times in analysis of large data sets. Genes that are coexpressed at the mRNA level commonly encode protein products that participate in the same pathway or process (66–68). Since the pioneering efforts of Su et al. (69) to generate the SymAtlas (now BioGPS; <http://biogps.org>) from sets of microarray data from mouse and human tissues, there have been numerous gene expression “atlases” across multiple tissues and within tissues across cell types and developmental time. The network tool BioLayout *Express*<sup>3D</sup> was developed to allow the visualization of coexpression relationships in large data sets (70, 71) and was used to dissect the mouse BioGPS data set (67) and subsequently in a meta-analysis of publicly available mouse (72) and human data (73) relating to hematopoietic differentiation and macrophage biology and in a preliminary pig expression atlas (66). BioLayout analysis was used to identify a large set of coexpressed genes that were most highly expressed in phagocytes and that encoded proteins associated with lysosomes, including all of the components of the vacuolar ATPase proton pump and lysosomal hydrolases. This lysosomal/endocytosis cluster of coexpressed genes included those encoding transcription factors such as PU.1 and C/EBP (CCAAT/enhancer-binding protein) that likely contribute to transcriptional control in macrophage differentiation, and indeed can drive differentiation to a phagocyte phenotype when expressed in fibroblasts (74). The promoters of these phagocyte-enriched genes, in common with those of known human lysosomal proteins (75), contained purine-rich motifs, binding sites for the macrophage transcrip-

tion factor PU.1, and the recognition motifs for basic helix-loop-helix transcription factors of the microphthalmia transcription factor family: MITF, TFEB, TFEC, and TFE3. All four MITF family members are expressed in macrophages. TFEC is a macrophage-specific transcription factor and itself a PU.1 target gene (76). MITF interacts both physically and genetically with PU.1 (34) and can transactivate the promoter of the ACP5 lysosomal enzyme gene (34).

By contrast to the clear coexpression of phagocyte-specific genes, the genes encoding surface antigen markers, recognized by monoclonal antibodies, that are commonly used to divide monocytes and macrophages into subpopulations, were not stringently coexpressed with either phagocytic function or with each other. The gene encoding the well-studied macrophage marker EMR1 (F4/80), for example, was in a very small coexpression cluster with the gene for a transcription factor, MAFB, that was subsequently shown to regulate its expression (77, 78). High expression of F4/80 was proposed as a marker for tissue macrophages that derive from yolk sac progenitors (44). The clear lack of correlation between surface markers is important because it means that we cannot predict the gene expression or surface antigen profile of individual cells based on the presence of any marker. Each of the proteins we regard as surface markers has a function and has its own intrinsic regulation.

One of the most prevalent uses of surface markers is the separation of macrophages from dendritic cells (DCs) and the segregation of both populations into subpopulations. The activation of T lymphocytes requires the presentation of the antigen on major histocompatibility complex (MHC) molecules on the surface of an antigen-presenting cell (APC). For some groups, the term “dendritic cell” has been merged with “antigen-presenting cell.” The problem with this view is that antigen presentation is a regulated pathway, and the genes involved are not correlated with any other cellular function. For some significant time, the integrin CD11c (ITGAX) was considered a DC marker in mice, even though it was clearly expressed by many tissue macrophage populations (6, 79). In the cluster analysis of mouse BioGPS data, CD11c was not coexpressed with any other marker (67).

The original description of the classical DC by Steinman and Cohn made the clear distinction that “unlike macrophages, they do not appear to engage in active endocytosis” (80). Analysis of large transcriptomic data sets reveals that the *a priori* definition of cells as DCs currently groups together cells with very distinct



transcriptional profiles (6, 17, 79, 81, 82). The Immunological Genome Consortium (ImmGen) produced transcriptomic profiles from a large number of different myeloid cell populations isolated from multiple mouse tissues based on cell surface marker expression, and proposed distinct expression signatures unique to DCs and macrophages (83, 84). Their analysis concluded that MHC class II (MHC-II) and the transcriptional regulator *CIITA* were part of a DC signature, which was predictable given the selection of MHC-II-negative macrophages for comparison. A separate analysis of the entire data set failed to identify coexpressed genes that correlated with the *a priori* definition of cells as macrophages or DCs (85). Even within this large myeloid-specific data set, there was no correlation between any of the cell surface receptors, such as CD11b, CD11c, F4/80, MHC-II, CD64, CSF-1R, and FLT3, that are commonly used to classify subpopulations or cell types of macrophages and DCs. As discussed in detail previously (6), this lack of correlation between markers is supported by both fluorescence-activated cell sorter profiling and immunohistochemistry, where the number of subpopulations that can be defined is a function of the number of markers examined.

With respect to the macrophage-DC distinction, meta-analysis of large microarray data sets from mouse and human (72, 73) produced the same conclusion as analysis of the ImmGen data; cells annotated as DCs clearly segregated into two groups. As one might have predicted based on the original definition of the DC, the expression cluster that divided all macrophage/DC-related networks into two clear classes was the cluster containing lysosomal/endocytosis genes described above. The classical DCs isolated as defined by Steinman had very low expression of all of the genes in this cluster, and lower expression of the putative regulators (PU.1, C/EBP, and MITF family), whereas there was a separate class of cells that included monocyte- and bone marrow-derived cells described as “DCs” and many MHC-II-positive myeloid cells from tissues, which were clearly capable of being active phagocytes based on their expression of the large endocytic cluster (67, 72, 81).

The only transcriptional signature associated with APC activity in both macrophages and “DCs” is a very small one, including MHC-II, CD74, and the regulator *CIITA*. Several recent reviews (82, 86, 87) have considered the transcriptional control in the development of the classical DC, and the BioGPS and ImmGen data confirm the separation of these cells from macrophages. The data also confirm some of the lineage-restricted transcription factors in mice that distinguish the classi-

cal, FLT3-dependent DC from the macrophage (86). The transcription factors that most clearly define classical DCs, such as BATF3 and ZBTB46, are transcriptional repressors. One of the functions of these transcription factors could be to block macrophage differentiation and expression of endocytic function (88).

The ImmGen data were also used to define a number of surface markers that positively identify “macrophages” as distinct from “DCs,” including the Fc receptor CD64 and the signaling molecule MERTK (83). These two markers did not correlate with each other in our reanalysis of the ImmGen data. CD64 is a direct target of CSF-1 signaling in mice and has been considered a marker, alongside CD163, of M2 polarization (89). CD64 is absent from elicited peritoneal macrophages, whereas MERTK is very highly expressed and further induced by lipopolysaccharide (LPS) (<http://biogps.org>). Therefore, like CD11c discussed above, their expression is state specific, and they cannot be considered as markers for a definitive “macrophage” or “DC.” The shortcomings of CD64 as a marker are illustrated by a study of dermal myeloid cells. CD64 was used to distinguish CD11b<sup>+</sup> macrophages from CD11b<sup>+</sup> DCs in the dermis, leading to the conclusion that only ~10% of the CD11b<sup>+</sup> myeloid cells in the dermis are macrophages (90, 91). The CD11b<sup>+</sup> “DCs” were monocyte derived and expressed most other macrophage “markers” (e.g., F4/80, CD68, and lysozyme) (90, 91). Alongside Langerhans cells of the epidermis, the vast majority of dermal myeloid cells expressed a *Csf1r*-EGFP (enhanced green fluorescent protein) transgene and were completely ablated by treatment of mice with anti-CSF-1R antibody (59). A recent proposal for a unified nomenclature that separates macrophages and DCs based on ontogeny and growth factor dependence would clearly separate the CD11b<sup>+</sup> DCs in skin, which are CSF-1 dependent, from classical DCs, which depend on FLT3 ligand (92). This distinction would also separate the putative classical DC subclasses in mouse, cDC1 and cDC2, which differ in expression of the chemokine receptor XCR1 (GPR5) and CD8 (86). Within the BioGPS data, the CD8<sup>+</sup> DCs express *Gpr5* at high levels and lack *Csf1r*. Plasmacytoid DCs also lack *Csf1r* mRNA. Conversely, the CD8<sup>−</sup> DCs lack GPR5 and expressed both *Csf1r* and *Flt3*, and detectable EMR1 (F4/80). It is not clear that the markers are expressed on the same cells within this population. What is clear is that the definition of cDC2s as distinct from macrophages is rather more contentious (86).

The separation of cell populations based on cell surface markers is clearly a mainstream technology in

immunology. Objections to the use of markers are not solely semantic. The core problem lies with the concept of a marker. A marker is only useful if it actually predicts function. Markers expressed by T lymphocytes such as CD3, CD4, and CD8 are informative, and predictive, because they are required for the function of the cells in which they are expressed, and they are, in fact, very well correlated with expression of genes required for lineage-specific function. The endosome/lysosome gene cluster discussed above is also clearly linked to function. Any one of the genes present within that cluster has a predictive value as a marker; a cell that expresses it is likely to be phagocytic. On the other hand, CD11b and CD11c encode complement receptors that have no function in antigen presentation. They are clearly likely to be required for complement receptor function, but there is no reason *a priori* to suspect that they will be highly expressed in APCs. The obvious counterargument is that markers are useful; they can be used to purify populations of cells that are enriched for a particular function of interest. However, the expression data tell us that such populations are intrinsically heterogeneous.

## GENETIC VARIATION AND MACROPHAGE BIOLOGY

Like the studies of macrophage ontogeny above, the ImmGen and BioGPS data sets and much of the literature on antigen presentation and DC/macrophage divergence derive from the C57BL/6 mouse. In mice, many tissue macrophages, and cells grown in CSF-1, lack MHC-II, whereas in most other species, including humans and pigs, monocytes and monocyte-derived macrophages (MDMs) are strongly MHC-II positive. Furthermore, the C57BL/6 mouse has only one MHC-II locus since H2-Ea is absent. This locus is inducible by LPS in macrophages from BALB/c mice (93). C57BL/6 macrophages do not express cathepsin E, which is needed for antigen processing (93). A gene promoter polymorphism in the arginine transporter, *Slc7a2*, means that C57BL/6 mice have very different rates of arginine metabolism than other strains (94). At least 65 genes distinguish the transcriptome of C57BL/6 macrophages absolutely from BALB/c macrophages (93), including the C1q components proposed as unique markers for microglia (95), which were much more highly expressed and inducible in C57BL/6 than in BALB/c mouse macrophages (93). Strain-specific variation in gene expression is also reflected in allele-specific methylation patterns in macrophages from an F1 cross between these strains (96), and there is similar diversity between other mouse strains (97, 98). This means that a

view of the MPS or the macrophage transcriptome based on the biology of the C57BL/6 mouse may not be generalizable to all mice, let alone to other species.

## TRANSCRIPTIONAL REGULATION AND MACROPHAGE DIFFERENTIATION

Whether or not tissue macrophages derive from definitive progenitors in the marrow, and must transit through a blood monocyte precursor, it is possible to isolate committed progenitor cells from bone marrow that express receptors for hematopoietic growth factors, and to use those growth factors to generate relatively pure populations of macrophages (in CSF-1), classical DCs (in FLT3L), or macrophages with APC activity (in granulocyte-macrophage CSF [GM-CSF]; otherwise called bone marrow-derived DCs). Some of the underlying transcriptional regulation of lineage commitment in mice has been inferred from large-scale transcriptomic profiling of purified progenitor cells (99–102). Similarly, there have been detailed transcriptomic studies of the differentiation of human blood monocytes to mature macrophages, or DCs, in the presence of CSF-1 or GM-CSF (103, 104). The process of macrophage differentiation can also be modeled to some extent using myeloid leukemia cell lines. The FANTOM4 (Functional Annotation of the Mammalian Genome) consortium used the THP-1 human monocytic leukemia line to study the cascade of transcriptional events associated with macrophage differentiation (105). Genome-scale 5' rapid amplification of cDNA ends (5' RACE; also known as cap analysis of gene expression [CAGE]) was used in parallel with microarrays to identify changes in promoter activity with time and to infer the transcription factors involved. One of the most interesting findings was the rapid downregulation of a large cohort of transcriptional regulators, exemplified by c-MYB, and the finding that small interfering RNA-mediated downmodulation of those factors was sufficient to drive the differentiation process (105).


The largest data sets available for human macrophage differentiation have come from the FANTOM5 consortium, which also utilized CAGE to identify the sets of promoters and enhancers utilized by hundreds of different cells and tissues (106, 107). These data sets include multiple samples of different human myeloid lineages, including multipotent progenitors (CD34<sup>+</sup> stem cells), common myeloid progenitors (CMPs), and granulocyte-macrophage progenitors (GMPs), three monocyte subsets defined by CD14 and CD16 expression, MDMs (grown in CSF-1), monocyte-derived “DCs” (MDCs;

grown in GM-CSF plus IL-4), Langerhans cells (LC) and migratory DCs from skin lymphatics. Although there are subtle differences in experimental systems and purification protocols, the data complement and parallel two large data sets generated by the Blueprint consortium, one of which profiled transcriptional regulation in isolated human progenitor cells (99), and another which detailed the human monocyte response to CSF-1 and tolerization with LPS (108).

The expression profiles of myeloid lineage cells have been analyzed separately from the complete FANTOM5 data set (109) and data access provided on a separate portal at <http://www.myeloidome.roslin.ed.ac.uk>. This portal enables visualization of the transcription start sites and expression profiles in this set of myeloid cell types of any gene of interest, using the genome browser. It also summarizes expression profiles of long noncoding RNAs and microRNAs and cell type enhancers that correlate in their expression with promoters in the same genomic region.

Figure 1 shows the expression levels of key growth factor receptors in a macrophage-DC differentiation series extracted from the human FANTOM5 gene expression data. The combined total expression of these five growth factors was remarkably similar across all cell types, but the proportion of total expression contributed by each gene varied considerably. Consistent with the identity of the samples, *KIT* (receptor for stem cell factor), *FLT3*, *CSF2RB* (GM-CSFR), and *CSF3R* (G-CSFR) are expressed in progenitors, the CD34<sup>+</sup> multipotent stem cells (MSCs), the CMPs, and the GMPs. *Csf1r* is first expressed in the GMPs. Outside of the progenitor population, *Csf1r* and *FLT3* show opposite expression patterns; the classical DCs express *FLT3* and all other populations, including monocyte-derived “DCs” and Langerhans cells of the skin (sometimes regarded as DCs), express *Csf1r*. As expected, given the clinical use of G-CSF for stem cell mobilization, *CSF3R* is expressed in the CD34<sup>+</sup> progenitors, but interestingly, its expression is retained in CD14<sup>+</sup> mono-

**FIGURE 1** Expression of selected genes encoding myeloid-restricted growth factor receptors. Stacked bars show expression of each gene in the cell type (normalized tags per million) derived from FANTOM5 CAGE data for human cells (107). Cell types are presented in the order of maturation: CD34<sup>+</sup> MSCs; CMPs; GMPs; migratory DCs; CD14<sup>++</sup> monocytes (CD14<sup>++</sup> Mo); CD14<sup>+</sup>CD16<sup>+</sup> monocytes (CD14<sup>+</sup>, CD16<sup>+</sup> Mo); CD16<sup>+</sup> monocytes (CD16<sup>+</sup> Mo); MDMs (cultured in CSF-1); monocytes cultured in GM-CSF (MDCs); and migratory DCs from skin lymphatics (LC).





cytes and downregulated with maturation in response to CSF-1, varying inversely with *Csf1r* mRNA. The expression of *CSF3R* in monocytes and their progenitors may be related to the finding that G-CSF treatment of humans mobilizes a population of monocytes that retain expression of CD34 (110).


As we concluded from a meta-analysis of published human microarray data (73), the transcriptional profiles of monocyte-derived populations grown in different growth factors clustered together, first and foremost because of their shared expression of phagocytic genes and some endocytic receptors (109). Many transcripts were more highly expressed in monocyte-derived macrophages grown in CSF-1 (*ACP5*, *CD163*, *C1Q*, tetraspanins, *IGF1*, *VEGFB*, scavenger receptors, and *CHI3L1*) or the monocytes grown in GM-CSF (*CD1A*, *-B*, *-C*, and *-E*; *DCSTAMP*; *CLEC4A*; *CLEC10A*; *CLEC4G*; and *TNFRSF11A*, also known as *RANK*). As in other data sets discussed above, the MHC-II genes were separately clustered because they are also expressed by monocytes and their committed progenitors. As expected, the monocyte-derived “DC” cells, grown in GM-CSF, maintained higher levels of the MHC-II cluster, whereas these genes were somewhat repressed in the monocytes grown in CSF-1.

The three human monocyte populations in the FANTOM5 data set were also subjected to detailed chromatin analysis, providing global maps of H3K4me1 (promoter) and H3K27ac (enhancer) locations that largely confirmed the CAGE data (111). The CAGE-based methodology also permitted identification of regulated enhancer activity, enabling, for example, the identification of active enhancers responsible for the differential expression of *CD14* in the monocyte subpopulations. Over all, the FANTOM5 data supported the view that the monocytes are a CSF-1-dependent differentiation series, with the intermediate monocytes showing intermediate expression of the vast majority of the hundreds of genes that showed differential expression between the two extremes of monocyte phenotype. This pattern includes *Csf1r* itself, which is 3-fold elevated in CD16<sup>++</sup> monocytes. The one exception, consistent with findings of others (reviewed in references 10–12), is ~2-fold elevation of a subset of MHC-II (HLA-DP, HLA-DQ, and HLA-DR) transcripts in the intermediate cells relative to CD14<sup>++</sup> and CD16<sup>++</sup> extremes, despite a progressive decline in expression of the regulator *CIITA*. If monocytes are a differentiation series, the selective increase in the intermediate population reported in many clinical settings probably represents a change in transit time between the states.

Aside from CD14 and CD16, two other markers have been proposed to provide functional delineation of subsets of human monocytes: TIE2 and SLAN (10, 12). The former encodes a tyrosine kinase receptor for angiopoietin-2, but it was not detected in any of the monocyte preparations in FANTOM5, where it was highly expressed as expected in endothelial cells. SLAN is an antigen formed by a novel O-linked 6-sulfo-LacNac modification of P-selectin glycoprotein ligand (PSGL1). PSGL1 is itself around 2 times more highly expressed in CD16<sup>++</sup> monocytes than CD14<sup>++</sup> monocytes. However, the enzyme most likely to be required for the modification, carbohydrate sulfotransferase 2, was undetectable in CD14<sup>++</sup> monocytes, induced in intermediate cells, and highly expressed in CD16<sup>++</sup> cells. One other marker, CD43, has been used in other species as a subset marker (10, 12), and the FANTOM5 data demonstrate that it is likely to provide a similar discrimination of the CD16<sup>++</sup> subset in humans.

The analysis of monocyte subsets by FANTOM5 identified the coregulation of genes required for glycolytic metabolism and the metabolic burst in the classical monocytes (111). Conversely, the CD16<sup>++</sup> monocytes were apparently more committed to oxidative metabolism and mitochondrial energy generation. It may be that the more mature, long-lived monocytes adapt with time to the aerobic environment of the bloodstream, where the “inflammatory” monocytes are adapted to enter the relatively low-oxygen environments of tissues and inflammatory sites. Among the genes strongly downregulated in the CD16<sup>++</sup> monocytes is the hypoxia-inducible transcription factor *HIF1A* and the glucose transporter *GLUT3* (*SLC2A3*).

About two-thirds of the annotated transcription factors in the genome can be detected in some state of differentiation or activation of the macrophage lineage. Most do not vary greatly in their expression across myeloid lineages. About 100 transcriptional regulators showed significant variation with differentiation in the populations shown in Fig. 1. An analysis of the monocyte cell types based on expression of 108 transcription factor and growth factor receptor genes was performed using BioLayout Express<sup>3D</sup> (70). Eleven coexpression clusters containing three or more genes were identified. The patterns of these 11 clusters are shown in Fig. 2, and their profiles are summarized in Table 1. The largest cluster consisted of the set of transcription factor genes that was expressed in progenitors and downregulated with differentiation. All of these genes were highly expressed in C57BL/6 mouse progenitor cells and downregulated with differentiation (<http://biogps.org>). Many



**FIGURE 2** Network layout of 108 growth factor receptor and transcription factor genes in myeloid lineages. Nodes represent genes and edges correlation between expression patterns of genes at a Pearson correlation coefficient of 0.74 or greater. Nodes of the same color form a cluster. Histograms show the average expression pattern of genes within the cluster. x axis, cell type. Each column represents one cell type, presented in the order of maturation: CD34<sup>+</sup> mesenchymal stem cells; CMPs; GMPs; migratory DCs; CD14<sup>+</sup> monocytes; CD14<sup>+</sup>CD16<sup>+</sup> monocytes; CD16<sup>+</sup> monocytes; MDMs (cultured in CSF-1); monocytes cultured in GM-CSF; and migratory DCs from skin lymphatics. Column colors are the same as the nodes in the cluster. y axis, average expression of genes in the cluster (normalized tags per million) derived from FANTOM5 CAGE data for human cells (107).

of them were also expressed constitutively by THP1 cells and downregulated in response to phorbol myristate acetate-induced differentiation (105).

Among these coregulated transcription factors, clusters 3 and 6 were expressed most highly in the classical monocytes and declined with maturation to the CD16<sup>+</sup>

subset, and still further in response to differentiation *in vitro*. Conversely, cluster 4 included transcription factors such as *CEBPB*, *MAFB*, and *TFEB* that increased with monocyte differentiation and still further in response to CSF-1 *in vitro*. The results are broadly consistent with a recent review of monocyte differentiation

**TABLE 1** Coexpression of transcription factor genes in cells of myeloid lineages<sup>a</sup>

Cluster	Description	Transcription factor genes
1	High in precursors (FLT3 <sup>+</sup> , KIT <sup>+</sup> )	<i>BACH2, DACH1, E2F1, E2F3, EGR1, ERG, ELF2, FOXP1, GFI1, GFIB, HOXA9, JUN, JUNB, LMO2, MYB, MYC, MYCN, NFE2, PRDM8, RFX8, RUNX1, SOX12, TAL, TCF3, TCF4</i>
2	High in precursors and monocytes; down in MDMs, MDCs, and G-CSFR <sup>+</sup>	<i>ELF1(A), ETS2, FLI1, FRA2, KLF7, PER1, PER2, SMAD3</i>
3	Declines with maturation from MSCs through monocyte subsets to MDMs/MDCs; retained in LCs	<i>ATF3, FOSB, FRA1, IRF6, JUN, MAFF, NFATC1, NR4A1, NR4A2</i>
4	Highest in monocytes and MDMs, increased in CD16 <sup>+</sup> monocytes	<i>CEBPB, IRF7, KLF2, LMO2 (C), MAFB, NR1D1, POU2F2, TCF7L2, TFEB</i>
5	Highest in SCs, migratory DCs, and LCs; declines with monocyte maturation	<i>ARNT, BHLHE40, ETV3, ID2, NR4A3, PRDM1, REL, RELB, ZBTB46</i>
6	Highest in CD14 <sup>+</sup> monocytes, declines in CD16 <sup>+</sup> , and suppressed in MDMs/MDCs	<i>CEBPD, FOS, HIF1A, JDP2, KLF4, MEF2C</i>
7	Induced in MDMs, low in all others	<i>BHLHE41, EGR2, ETV5, MAF, MITF, NR1H3 (LXRA), PPARG</i>
8	Induced in both MDMs and MDCs	<i>CREG1, PPARG, SNAI3, TFEC</i>
9	High in MDCs, also increased in MDCs and LCs	<i>ARNTL2, CIITA, IRF4, SPIB</i>
10	High in SCs, down in CMPs	<i>ETS1, SMAD7, SOX4</i>
11	High in MDCs (GM-CSFR <sup>+</sup> )	<i>CEBPA, FOXQ1</i>

<sup>a</sup>Cluster numbers are derived from the BioLayout Express3D analysis shown in Fig. 2. Transcription factors are those with high expression in the cluster. MDM, monocyte-derived macrophage (cultured in CSF-1); MDC, monocyte cultured in GM-CSF plus IL-4; LC, Langerhans cell. Migratory DCs are cells isolated from skin lymphatics.

by Huber et al. (112) but greatly extend the transcriptional network. In every case, the CD14<sup>+</sup>CD16<sup>+</sup> cells have intermediate expression, again reinforcing the view that they are a differentiation intermediate between the CD14<sup>++</sup>CD16<sup>-</sup> and CD14<sup>-</sup>CD16<sup>++</sup> subsets. A number of genes of interest have idiosyncratic expression patterns and are not included in clusters (not shown). For example, *BATF3*, the mouse DC regulator mentioned earlier, was expressed in human monocytes and increased markedly with maturation to the CD16<sup>++</sup> subset. It was maintained in monocytes grown in GM-CSF but ablated in those grown in CSF-1. In mice, the generation of the Ly6C<sup>-</sup>, or nonclassical, monocyte subset depends on the CSF-1-responsive early response gene *Nr4a1* (Nur77) (113). The *Nr4a1* gene was a member of cluster 3, and it is likely that NR4A1 protein also performs some function in maturation in human monocytes.

### CSF1R, THE ARCHETYPAL MACROPHAGE-SPECIFIC GENE

The CSF-1 receptor (*Csf1r*) locus has been studied in great detail to provide an understanding of the processes of macrophage differentiation. Expression of *Csf1r* mRNA is one of the earliest markers of macrophage lineage commitment from multipotent progenitors in mouse bone marrow, as well as the appearance of macrophages in the yolk sac (32, 114). In the mouse, CSF-1 was shown to direct myeloid lineage fate in single multipotent HSCs by activating the expression of tran-


scription factor PU.1 (115). This finding appears incompatible with human and mouse transcriptomic data (both in FANTOM5 and in BioGPS), which indicate that *Sp1* (encoding PU.1) is already highly expressed in CD34<sup>+</sup> MSCs, whereas *Csf1r* is first detectable in GMPs (see Fig. 1). Further, the TATA-less, macrophage-specific promoter of the *Csf1r* locus in both species contains multiple PU.1/ETS binding sites that are bound by PU.1 and required for maximal activity (116, 117), and PU.1 is required for *Csf1r* expression in progenitor cells (116). Hence, a model that places PU.1 downstream of CSF-1R signaling does not fit the available expression data. Tagoh et al. (114) purified mouse c-KIT-positive progenitors and confirmed that (i) they express c-MYB and PU.1 and (ii) they lack surface CSF-1R as well as *Csf1r* mRNA. These cells require a cocktail of IL-1, IL-3, and CSF-1 to drive macrophage differentiation. The critical event that permits the expression of *Csf1r* and lineage commitment is more likely loss of c-MYB rather than induction of PU.1 (118). Detailed studies of the chromatin structure of the mouse *Csf1r* locus during differentiation of progenitors (114) revealed the occupation of both purine-rich motifs and C/EBP binding sites in the *Csf1r* promoter in the immature precursors, consistent with expression of both PU.1 and CEBP family members in these cells. These findings indicated that regulatory elements elsewhere in the locus drive transcriptional activation of *Csf1r* transcription during differentiation. Multiple analyses of transcription factor binding site occupancy and epigenetic profiles in mouse and human

provide a consistent view of potential regulatory elements in the *Csf1r* locus (104, 111, 119, 120), summarized in Fig. 3.

The purine-rich promoter architecture of *Csf1r* is shared by other myeloid-specific promoters, and basal activity requires cooperation between PU.1 and other ETS family transcription factors (121) as well as binding of Ewing sarcoma protein or the related FUS/TLS to the transcription start site (TSS) (122). Multiple ETS family members expressed in precursors and monocytes

(ERG, ELF2, ELF1, ETS2, FLI1, ETV3, and ETV5; Table 1) are likely to fulfil the role of cooperating with PU.1 to activate purine-rich promoters. Conserved candidate enhancer sites upstream of the major macrophage *Csf1r* TSS, and within several introns, are also evident in chromatin analysis (104, 111, 119, 120), and the enhancer activity was confirmed based on bidirectional promoter activity in data from both human and mouse macrophages from the FANTOM5 consortium (106, 107). All mammalian *Csf1r* genes contain a con-

**FIGURE 3** Chromatin architecture of the mouse and human *Csf1r* loci. Genome browser tracks of indicated histone modifications and transcription factors associated with enhancer elements are shown. The filled green box indicates the macrophage promoter. Boxes in blue identify intergenic and intragenic enhancer candidates. FIRE is represented by a filled blue box. Chip-Seq data sets that formed the basis of this figure for human macrophages are from derived from references 104 and 159. The mouse PU.1 track is derived from reference 136, and other mouse tracks from ENCODE.



served intronic enhancer referred as the Fms intronic regulatory element (FIRE) (123, 124). Tagoh et al. (114) demonstrated by *in vivo* footprinting that activation of mouse *Csf1r* transcription in c-KIT-positive precursors involves sequential occupation of multiple sites in the FIRE region. FIRE provides a remarkable cluster of highly conserved binding sites for many of the regulated transcription factors shown in Table 1, notably GC-rich elements likely bound by EGR1/EGR2 and KLF family members (104, 116, 125).

*Csf1r* reporter mice have been especially useful for studies of both CSF-1 and anti-CSF-1R treatments (55, 59, 126). A *Csf1r*-EGFP reporter containing the *Csf1r* promoter plus FIRE was detectable in all myeloid cells throughout the body, generating the MacGreen mouse (123) as well as constitutive and tamoxifen-inducible *Csf1r*-Cre transgenes used in lineage trace studies (44, 127). A 150-bp distal promoter element, containing a conserved AP1 site, is required for expression in mature macrophages and osteoclasts (128). The MacBlue transgenic line (*Csf1r*-ECFP [enhanced cyan fluorescent protein]) was generated using a promoter with this element deleted (129, 130). The reporter protein was expressed on macrophages as they appeared in the yolk sac and provided a striking picture of their abundance during embryonic development (30). Unexpectedly, the expression disappeared from the majority of tissue macrophages postnatally, whereas expression was retained in blood monocytes and their progenitors, and in the IL-34-dependent populations, the microglia and Langerhans cells in the skin (30). Even in the gut, where the macrophage population clearly derives from continuous renewal from monocytes (46), the *Csf1r*-ECFP transgene was extinguished in the majority of resident macrophages. The transgene therefore permits live imaging of monocyte trafficking (131).

Expression of the reporter genes based on the *Csf1r* locus requires the activity of FIRE (123), and the activity of FIRE is functionally conserved across mammalian species (132). FIRE is conserved also in the *Csf1r* locus of birds, and *Csf1r* reporter transgenic chickens have been produced in which all of the macrophages are labeled from the earliest yolk sac-derived cells (133). The chick provides an alternative model to study the origin of macrophages, and is the model in which the yolk sac-derived macrophages were first described (35, 134). Using transgenic reporters, we found that macrophages derived from the yolk sac are capable of extensive proliferation in response to CSF-1 *in vitro*, and in response to CSF-1 administration into the embryo. When transplanted to a nontransgenic recipient, they give rise to

macrophages all over the body. However, these cells are not retained anywhere after hatching. By contrast, transplantation of cells from hatchling bone marrow into embryos prior to the onset of definitive hematopoiesis produced extensive macrophage chimerism in the embryo that was retained in mature adult birds, and which included regeneration of macrophage progenitors of donor origin in the marrow (36). We suggest that the trophic environment of the early embryo can only support the committed macrophage progenitors, perhaps similar to those of mouse (37). In keeping with the earliest findings using chick-quail yolk sac chimeras (134), these findings suggest that the contribution of the yolk sac to tissue macrophage populations is transient, and yolk sac-derived cells are replaced entirely by the progeny of definitive hematopoiesis.

## TISSUE-SPECIFIC ADAPTATION AND ACTIVATION OF MACROPHAGES

Regardless of the embryonic origin, each population of tissue-resident macrophages adapts specifically to the environment in which it finds itself. Sample-to-sample comparison of the extensive ImmGen data set for the mouse demonstrated that each tissue macrophage population formed a distinct cluster (81). One recent study focused on the differentiation of microglia, the macrophages of the brain, and identified a marker set that distinguished these from blood monocytes and from tissue macrophages isolated from other locations (95). The BioGPS data, the FANTOM5 data, and the ImmGen data all include strongly validated microglial data sets. The former two confirm known microglial-enriched genes including *Aif1* (*Iba1*) and the scavenger receptors *Fcrls* and *Marco* but do not support others such as *C1q* and *Csf1r*, which are also highly expressed in other macrophage populations. A more extensive comparison combined expression profiling of isolated mouse tissue macrophage populations with extensive analysis of chromatin architecture (135, 136). Several of the genes that marked particular macrophage populations were transcription factors, notably *Sall1* and *Mef2c* in microglia, *Gata6* in peritoneal macrophages, *Lxra* in Kupffer cells, *Spic* in spleen, and *Runx3* in the gut (135). The expression of *Gata6* in mouse peritoneal macrophages appears to be required for their self-renewal and homeostasis; two groups separately reported on the select impact of myeloid-specific deletions of the gene in the resident peritoneal population (137, 138). The tissue-specific macrophage phenotypes correlated with the presence of H3K4Me1/2 enhancer profiles in their genomic



vicinity. The role of environment in the acquisition of tissue-specific phenotypes was examined in bone marrow chimeras. The outcomes indicated not only that the tissue determines the phenotype but, *inter alia*, that monocytes derived from bone marrow progenitors can, and do, give rise to tissue-resident macrophages if the niche is available.

There is considerably less data available on tissue-specific macrophage development from other species. However, the number of macrophages in most organs is sufficiently high that we can extract a macrophage signature without isolating the cells. Within the pig gene expression atlas, we profiled lung alveolar macrophages, blood monocytes, and bone marrow-derived macrophages alongside many different tissues (66). Comparative analysis revealed that alveolar macrophages express exceptionally high levels of a wide diversity of C-type lectin receptors (SIGLEC and CLEC family members) and Toll-like receptors (TLRs), presumably to deal with inhaled particles. This pattern is also evident in the many profiles of human alveolar macrophages that can be accessed through NCBI GEO. By contrast, in the wall of the gut we could detect a clear signature of the abundant lamina propria macrophage population, but the C-type lectins and TLRs were absent.

The apparent plasticity of tissue macrophages reflects, in part, their responsiveness to numerous different stimuli, some of which are tissue specific and others shared by locations or induced in response to environmental challenges. The generic term “activation” was originally applied to the ability of recruited macrophages to acquire microbicidal and tumoricidal activity in response to products of activated T cells. A number of groups have advocated subclassification of the activation states seen in recruited macrophages, broadly into M1 and M2 or classically activated and alternatively activated (5, 139–141). The M1 and M2 nomenclature links the state of activation of the macrophages to the activation of Th1 and Th2 lymphocytes, which in turn links them to the actions of gamma interferon (IFN- $\gamma$ ; originally known as macrophage-activating factor) (142) and IL-4. Interestingly, although it is not commonly regarded as a macrophage growth factor, IL-4 can promote macrophage proliferation in mice *in vivo* (57, 143).

The proposed M1/M2 dichotomy is not supported by genome-scale data (73). If there were coordinated M1 or M2 “regulons,” we would expect to see correlated expression of the classical marker genes for the putative M1 and M2 phenotypes across different cellular states, and this was not observed. The utility of the M1/M2

concept across species is also not clear. The gene expression profiles of “classically activated” mouse, pig, and human macrophages are very different (144), with the pig being rather more human-like (145). Similarly, the IL-4-inducible alternatively activated profiles, and putative M2 markers, are poorly conserved between mouse and human. Transglutaminase 2 was proposed as the only well-conserved marker (146). Mosser and Edwards (147) suggested that macrophage activation may better be described as a spectrum, analogous to a color wheel. Xue et al. (148) confirmed the spectrum model with an extensive comparison of human monocyte-derived macrophages grown in CSF-1 or GM-CSF and exposed to numerous distinct stimuli including IFN- $\gamma$ , IFN- $\beta$ , IL-4/IL-13, IL-10, glucocorticoids, TLR agonists, tumor necrosis factor, and prostaglandin. While there was a broad dichotomy between IFN- $\gamma$  (M1) and IL-4 (M2) directed states, addition of further stimuli segregated the transcriptional response into many separate modules, with 49 distinct coexpression clusters containing 27 to 884 genes per module (148). The simplistic view of macrophage activation that pervades the literature is based in part on simplified models in which individual agonists are studied individually, often at a single dose, a single time point, and in a single mouse strain and/or small subset of individuals. The problem with this approach is illustrated by several findings. IFN- $\gamma$  is normally made by activated T cells alongside GM-CSF. As the sole stimulus, IFN- $\gamma$  causes growth arrest, whereas when GM-CSF is present, it is a mitogen (149). On the matter of dose and mouse strain, the dose response to LPS differs at the single-gene level (some genes are induced only by higher doses), and profoundly between mouse strains (93, 98). And finally, in humans it has been shown that some 80% of genes in monocytes exhibit heritable differences in gene expression and there is a major divergence in the secondary induction of IFN- $\beta$  target genes in response to LPS (150).

A secondary issue is the massive heterogeneity of gene expression in macrophages at the single-cell level. Single-cell analysis of LPS-inducible genes in macrophages demonstrated essentially bimodal variation between individual cells; genes are either induced or they are not (151). The authors in this case sought causal explanations for this variation based on covariance of transcription factor expression at the single-cell level. However, an alternative view is that transcriptional activation at the individual gene level is intrinsically probabilistic (152). Stochastic variation in gene expression may occur even at the single-allele level. Indeed, the LPS receptor, TLR4, is expressed from only one allele in

individual cells, with an allele-counting mechanism similar to that of the X chromosome (153). This finding explains the semidominance of the *Tlr4* mutation in C3H/HeJ mice, since in heterozygotes 50% of cells express the nonfunctional protein. Conversely, when one allele is deleted, all cells express *Tlr4* (from the other allele). Furthermore, because of the complex feedback loops in stimulated cells, in which LPS rapidly induces inhibitors that block signaling and degrade induced mRNAs and proteins (154, 155), individual cells show an oscillating response over relatively short time frames, eventually reaching a new steady state (156).

Against this background of complexity and heterogeneity, Murray et al. (157) proposed a set of guidelines to be used when describing macrophage activation states. They propose that descriptions of macrophage activation in disease states accurately describe the system, the way populations were isolated, and then utilize markers to enhance the description. However, even this rigorous approach is confounded if each macrophage is unique, deploying the potential arsenal of host defense weaponry in distinct combinations that change with time. The plasticity and diversity of individual macrophages may be a necessary part of their innate immune function, enabling the generation of a combinatorial diversity that cannot readily be overcome by a single pathogenicity determinant. An alternative to cell-based models is to describe diseases in terms of interacting genes. For example, if one examines very large data sets of cancer expression arrays, it is possible to extract a set of coexpressed genes that includes many known phagocyte markers, and *inter alia* indicates that there is a common tumor-associated macrophage signature, regardless of tumor type, that fits neither M1 nor M2 profiles (85).

## DATABASES, WEBSITES, AND THE FUTURE

The escalating amount of data on mononuclear phagocyte biology coming from genome-scale technologies now taxes the capacity of any individual to access all of the useful information about the regulation of their favorite gene. BioGPS is an example of a new era of more user-friendly portals, as is the Immunological Genome portal (<http://www.immgen.org>). We established the website <http://www.macrophages.com> as a community website for sharing access to macrophage-related genomic and other information (158), including the massive promoter-related data sets arising from the FANTOM projects. Macrophages.com also provides macrophage-related pathway annotation data and

links to the growing InnateDB (<http://www.innateDB.org>), which curates molecular interactions among macrophage-expressed proteins. The website also contains a curated compendium of major reviews on macrophage biology and transcriptional regulation, many of which provide much more comprehensive coverage of subtopics than this brief overview. With completed genomes, we are seeing comparable data sets available for other species, including domestic pigs, chickens, sheep, and cattle, that will underpin more-rigorous studies of the evolution of innate immunity, and also the recognition that there is very substantial genetic variation within species that underlies disease susceptibility loci.

In summary, macrophages are a very diverse cell type, expressing a subset of surface markers and derived from both yolk sac and circulating monocytes. While useful information has been gained by studies of mice, primarily the C57BL/6 strain, these are not always generalizable to humans and other animals, and more-extensive studies of larger mammals such as pigs and sheep, as well as studies utilizing the flexibility and unprecedented developmental analysis of the chicken, will be needed to clarify the role, ontogeny, and differential function of the range of myeloid cells.

## ACKNOWLEDGMENTS

The Roslin Institute is supported by Institute Strategic Programme Grants from the Biotechnology and Biological Sciences Research Council.

## REFERENCES

1. van Furth R, Cohn ZA. 1968. The origin and kinetics of mononuclear phagocytes. *J Exp Med* 128:415–435.
2. Hume DA. 2006. The mononuclear phagocyte system. *Curr Opin Immunol* 18:49–53.
3. Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. 2002. The mononuclear phagocyte system revisited. *J Leukoc Biol* 72:621–627.
4. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. 2010. Development of monocytes, macrophages, and dendritic cells. *Science* 327:656–661.
5. Gordon S, Taylor PR. 2005. Monocyte and macrophage heterogeneity. *Nat Rev Immunol* 5:953–964.
6. Hume DA. 2008. Differentiation and heterogeneity in the mononuclear phagocyte system. *Mucosal Immunol* 1:432–441.
7. Hume DA, MacDonald KP. 2012. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. *Blood* 119:1810–1820.
8. Wynn TA, Chawla A, Pollard JW. 2013. Macrophage biology in development, homeostasis and disease. *Nature* 496:445–455.
9. Gordon S, Taylor PR. 2005. Monocyte and macrophage heterogeneity. *Nat Rev Immunol* 5:953–964.
10. Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. 2012. The three human monocyte subsets: implications for health and disease. *Immunol Res* 53:41–57.
11. Ziegler-Heitbrock L. 2014. Monocyte subsets in man and other species. *Cell Immunol* 289:135–139.

12. Ziegler-Heitbrock L. 2015. Blood monocytes and their subsets: established features and open questions. *Front Immunol* 6:423. doi:10.3389/fimmu.2015.00423.
13. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB. 2010. Nomenclature of monocytes and dendritic cells in blood. *Blood* 116:e74–e80. doi:10.1182/blood-2010-02-258558.
14. Geissmann F, Jung S, Littman DR. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. *Immunity* 19:71–82.
15. Bain CC, Mowat AM. 2014. The monocyte-macrophage axis in the intestine. *Cell Immunol* 291:41–48.
16. Epelman S, Lavine KJ, Randolph GJ. 2014. Origin and functions of tissue macrophages. *Immunity* 41:21–35.
17. Jenkins SJ, Hume DA. 2014. Homeostasis in the mononuclear phagocyte system. *Trends Immunol* 35:358–367.
18. Zigmond E, Jung S. 2013. Intestinal macrophages: well educated exceptions from the rule. *Trends Immunol* 34:162–168.
19. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE, Ivanov S, Duan Q, Bala S, Condon T, van Rooijen N, Grainger JR, Belkaid Y, Ma'ayan A, Riches DW, Yokoyama WM, Ginhoux F, Henson PM, Randolph GJ. 2013. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. *Immunity* 39:599–610.
20. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, Puel A, Biswas SK, Moshous D, Picard C, Jais JP, D'Cruz D, Casanova JL, Trouillet C, Geissmann F. 2010. Human CD14<sup>dim</sup> monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. *Immunity* 33:375–386.
21. Thomas G, Tacke R, Hedrick CC, Hanna RN. 2015. Nonclassical patrolling monocyte function in the vasculature. *Arterioscler Thromb Vasc Biol* 35:1306–1316.
22. Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, Hoffmann R, Lang R, Haniffa M, Collin M, Tacke F, Habenicht AJ, Ziegler-Heitbrock L, Randolph GJ. 2010. Comparison of gene expression profiles between human and mouse monocyte subsets. *Blood* 115:e10–e19. doi:10.1182/blood-2009-07-235028.
23. Hollox EJ, Hoh BP. 2014. Human gene copy number variation and infectious disease. *Hum Genet* 133:1217–1233.
24. Hussen J, Düvel A, Sandra O, Smith D, Sheldon IM, Zieger P, Schuberth HJ. 2013. Phenotypic and functional heterogeneity of bovine blood monocytes. *PLoS One* 8:e71502. doi:10.1371/journal.pone.0071502.
25. Fairbairn L, Kapetanovic R, Beraldi D, Sester DP, Tuggle CK, Archibald AL, Hume DA. 2013. Comparative analysis of monocyte subsets in the pig. *J Immunol* 190:6389–6396.
26. Yrlid U, Jenkins CD, MacPherson GG. 2006. Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state conditions. *J Immunol* 176:4155–4162.
27. Burke B, Ahmad R, Staples KJ, Snowden R, Kadioglu A, Frankenberger M, Hume DA, Ziegler-Heitbrock L. 2008. Increased TNF expression in CD43<sup>++</sup> murine blood monocytes. *Immunol Lett* 118:142–147.
28. Sunderkötter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, Leenen PJ. 2004. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. *J Immunol* 172:4410–4417.
29. Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guillems M, Misharin A, Hume DA, Perlman H, Malissen B, Zelzer E, Jung S. 2013. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* 38:79–91.
30. Sauter KA, Pridans C, Sehgal A, Bain CC, Scott C, Moffat L, Rojo R, Stutchfield BM, Davies CL, Donaldson DS, Renault K, McColl BW, Mowat AM, Serrels A, Frame MC, Mabbott NA, Hume DA. 2014. The MacBlue binary transgene (csf1r-gal4VP16/UAS-ECFP) provides a novel marker for visualisation of subsets of monocytes, macrophages and dendritic cells and responsiveness to CSF1 administration. *PLoS One* 9:e105429. doi:10.1371/journal.pone.0105429.
31. Naito M, Yamamura F, Nishikawa S, Takahashi K. 1989. Development, differentiation, and maturation of fetal mouse yolk sac macrophages in cultures. *J Leukoc Biol* 46:1–10.
32. Lichanska AM, Browne CM, Henkel GW, Murphy KM, Ostrowski MC, McKercher SR, Maki RA, Hume DA. 1999. Differentiation of the mononuclear phagocyte system during mouse embryogenesis: the role of transcription factor PU.1. *Blood* 94:127–138.
33. Lichanska AM, Hume DA. 2000. Origins and functions of phagocytes in the embryo. *Exp Hematol* 28:601–611.
34. Luchin A, Suchting S, Merson T, Rosol TJ, Hume DA, Cassady AI, Ostrowski MC. 2001. Genetic and physical interactions between microphthalmia transcription factor and PU.1 are necessary for osteoclast gene expression and differentiation. *J Biol Chem* 276:36703–36710.
35. Cuadros MA, Coltey P, Carmen Nieto M, Martin C. 1992. Demonstration of a phagocytic cell system belonging to the hemopoietic lineage and originating from the yolk sac in the early avian embryo. *Development* 115:157–168.
36. Garceau V, Balic A, Garcia-Morales C, Sauter KA, McGrew MJ, Smith J, Vervelde L, Sherman A, Fuller TE, Oliphant T, Shelley JA, Tiwari R, Wilson TL, Chintoan-Uta C, Burt DW, Stevens MP, Sang HM, Hume DA. 2015. The development and maintenance of the mononuclear phagocyte system of the chick is controlled by signals from the macrophage colony-stimulating factor receptor. *BMC Biol* 13:12. doi:10.1186/s12915-015-0121-9.
37. Hettinger J, Richards DM, Hansson J, Barra MM, Joschko AC, Krijgsvelde J, Feuerer M. 2013. Origin of monocytes and macrophages in a committed progenitor. *Nat Immunol* 14:821–830.
38. Swirski FK, Hilgendorf I, Robbins CS. 2014. From proliferation to proliferation: monocyte lineage comes full circle. *Semin Immunopathol* 36:137–148.
39. Yamamoto R, Morita Y, Ooehara J, Hamanaka S, Onodera M, Rudolph KL, Ema H, Nakauchi H. 2013. Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. *Cell* 154:1112–1126.
40. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* 330:841–845.
41. Chorro L, Sarde A, Li M, Woollard KJ, Chambon P, Malissen B, Kissenpfennig A, Barbaroux JB, Groves R, Geissmann F. 2009. Langerhans cell (LC) proliferation mediates neonatal development, homeostasis, and inflammation-associated expansion of the epidermal LC network. *J Exp Med* 206:3089–3100.
42. Hoeffel G, Wang Y, Greter M, See P, Teo P, Malleret B, Leboeuf M, Low D, Oller G, Almeida F, Choy SH, Grisotto M, Renia L, Conway SJ, Stanley ER, Chan JK, Ng LG, Samokhvalov IM, Merad M, Ginhoux F. 2012. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. *J Exp Med* 209:1167–1181.
43. Guillems M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prieck S, Deswarte K, Malissen B, Hammad H, Lambrecht BN. 2013. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. *J Exp Med* 210:1977–1992.
44. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, Jacobsen SE, Pollard JW, Frampton J, Liu KJ, Geissmann F. 2012. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science* 336:86–90.



45. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, Becker CD, See P, Price J, Lucas D, Greter M, Mortha A, Boyer SW, Forsberg EC, Tanaka M, van Rooijen N, Garcia-Sastre A, Stanley ER, Ginhoux F, Frenette PS, Merad M. 2013. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity* 38:792–804.
46. Bain CC, Bravo-Blas A, Scott CL, Gomez Perdiguero E, Geissmann F, Henri S, Malissen B, Osborne LC, Artis D, Mowat AM. 2014. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. *Nat Immunol* 15:929–937.
47. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, Wieghofer P, Heinrich A, Riemke P, Hölscher C, Müller DN, Luckow B, Brocker T, Debowski K, Fritz G, Opdenakker G, Diefenbach A, Biber K, Heikenwalder M, Geissmann F, Rosenbauer F, Prinz M. 2013. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. *Nat Neurosci* 16:273–280.
48. Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, Garner H, Trouillet C, de Bruijn MF, Geissmann F, Rodewald HR. 2015. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. *Nature* 518:547–551.
49. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, Brija T, Gautier EL, Ivanov S, Satpathy AT, Schilling JD, Schwendener R, Sergin I, Razani B, Forsberg EC, Yokoyama WM, Unanue ER, Colonna M, Randolph GJ, Mann DL. 2014. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. *Immunity* 40:91–104.
50. Sheng J, Ruedl C, Karjalainen K. 2015. Most tissue-resident macrophages except microglia are derived from fetal hematopoietic stem cells. *Immunity* 43:382–393.
51. Hoeffel G, Chen J, Lavin Y, Low D, Almeida FF, See P, Beaudin AE, Lum J, Low I, Forsberg EC, Poidinger M, Zolezzi F, Larbi A, Ng LG, Chan JK, Greter M, Becher B, Samokhvalov IM, Merad M, Ginhoux F. 2015. C-Myb<sup>+</sup> erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. *Immunity* 42:665–678.
52. Hume DA, Perry VH, Gordon S. 1983. Immunohistochemical localization of a macrophage-specific antigen in developing mouse retina: phagocytosis of dying neurons and differentiation of microglial cells to form a regular array in the plexiform layers. *J Cell Biol* 97:253–257.
53. Perry VH, Hume DA, Gordon S. 1985. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. *Neuroscience* 15:313–326.
54. Nakamichi Y, Udagawa N, Takahashi N. 2013. IL-34 and CSF-1: similarities and differences. *J Bone Miner Metab* 31:486–495.
55. Gow DJ, Sauter KA, Pridans C, Moffat L, Sehgal A, Stutchfield BM, Raza S, Beard PM, Tsai YT, Bainbridge G, Boner PL, Fici G, Garcia-Tapia D, Martin RA, Oliphant T, Shelly JA, Tiwari R, Wilson TL, Smith LB, Mabbott NA, Hume DA. 2014. Characterisation of a novel Fc conjugate of macrophage colony-stimulating factor. *Mol Ther* 22:1580–1592.
56. Hume DA, Pavli P, Donahue RE, Fidler IJ. 1988. The effect of human recombinant macrophage colony-stimulating factor (CSF-1) on the murine mononuclear phagocyte system in vivo. *J Immunol* 141:3405–3409.
57. Jenkins SJ, Ruckerl D, Thomas GD, Hewitson JP, Duncan S, Brombacher F, Maizels RM, Hume DA, Allen JE. 2013. IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1. *J Exp Med* 210:2477–2491.
58. Bartocci A, Mastrogianis DS, Migliorati G, Stockert RJ, Wolkoff AW, Stanley ER. 1987. Macrophages specifically regulate the concentration of their own growth factor in the circulation. *Proc Natl Acad Sci U S A* 84:6179–6183.
59. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, Kuns R, Pettit AR, Clouston A, Wainwright B, Branstetter D, Smith J, Paxton RJ, Cerretti DP, Bonham L, Hill GR, Hume DA. 2010. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. *Blood* 116:3955–3963.
60. Pollard JW. 2009. Trophic macrophages in development and disease. *Nat Rev Immunol* 9:259–270.
61. Sudo T, Nishikawa S, Ogawa M, Kataoka H, Ohno N, Izawa A, Hayashi S, Nishikawa S. 1995. Functional hierarchy of *c-kit* and *c-fms* in intramarrow production of CFU-M. *Oncogene* 11:2469–2476.
62. Yao GQ, Wu JJ, Troiano N, Zhu ML, Xiao XY, Insogna K. 2012. Selective deletion of the membrane-bound colony stimulating factor 1 isoform leads to high bone mass but does not protect against estrogen-deficiency bone loss. *J Bone Miner Metab* 30:408–418.
63. De M, Sanford T, Wood GW. 1993. Relationship between macrophage colony-stimulating factor production by uterine epithelial cells and accumulation and distribution of macrophages in the uterus of pregnant mice. *J Leukoc Biol* 53:240–248.
64. Carreras E, Turner S, Paharkova-Vatchkova V, Mao A, Dascher C, Kovats S. 2008. Estradiol acts directly on bone marrow myeloid progenitors to differentially regulate GM-CSF or Flt3 ligand-mediated dendritic cell differentiation. *J Immunol* 180:727–738.
65. Gordon S. 2008. Elie Metchnikoff: father of natural immunity. *Eur J Immunol* 38:3257–3264.
66. Freeman TC, Ivens A, Baillie JK, Beraldi D, Barnett MW, Dorward D, Downing A, Fairbairn L, Kapetanovic R, Raza S, Tomoiu A, Alberio R, Wu C, Su AI, Summers KM, Tuggle CK, Archibald AL, Hume DA. 2012. A gene expression atlas of the domestic pig. *BMC Biol* 10:90. doi:10.1186/1741-7007-10-90.
67. Hume DA, Summers KM, Raza S, Baillie JK, Freeman TC. 2010. Functional clustering and lineage markers: insights into cellular differentiation and gene function from large-scale microarray studies of purified primary cell populations. *Genomics* 95:328–338.
68. van Dam S, Craig T, de Magalhães JP. 2015. GeneFriends: a human RNA-seq-based gene and transcript co-expression database. *Nucleic Acids Res* 43(Database issue):D1124–D1132.
69. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB. 2004. A gene atlas of the mouse and human protein-encoding transcriptomes. *Proc Natl Acad Sci U S A* 101:6062–6067.
70. Theodoridis A, van Dongen S, Enright AJ, Freeman TC. 2009. Network visualization and analysis of gene expression data using BioLayout Express<sup>3D</sup>. *Nat Protoc* 4:1535–1550.
71. Freeman TC, Goldovsky L, Brosch M, van Dongen S, Mazière P, Grocock RJ, Freilich S, Thornton J, Enright AJ. 2007. Construction, visualisation, and clustering of transcription networks from microarray expression data. *PLoS Comput Biol* 3:2032–2042.
72. Mabbott NA, Kenneth Baillie J, Hume DA, Freeman TC. 2010. Meta-analysis of lineage-specific gene expression signatures in mouse leukocyte populations. *Immunobiology* 215:724–736.
73. Mabbott NA, Baillie JK, Brown H, Freeman TC, Hume DA. 2013. An expression atlas of human primary cells: inference of gene function from coexpression networks. *BMC Genomics* 14:632. doi:10.1186/1471-2164-14-632.
74. Feng R, Desbordes SC, Xie H, Tillo ES, Pixley F, Stanley ER, Graf T. 2008. PU.1 and C/EBP $\alpha$  convert fibroblasts into macrophage-like cells. *Proc Natl Acad Sci U S A* 105:6057–6062.
75. Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P, Sardiello M, Rubinsztein DC, Ballabio A. 2011. TFEB links autophagy to lysosomal biogenesis. *Science* 332:1429–1433.
76. Rehli M, Lichanska A, Cassady AI, Ostrowski MC, Hume DA. 1999. TFEB is a macrophage-restricted member of the microphthalmia-TFE subfamily of basic helix-loop-helix leucine zipper transcription factors. *J Immunol* 162:1559–1565.

77. Moriguchi T, Hamada M, Morito N, Terunuma T, Hasegawa K, Zhang C, Yokomizo T, Esaki R, Kuroda E, Yoh K, Kudo T, Nagata M, Greaves DR, Engel JD, Yamamoto M, Takahashi S. 2006. MafB is essential for renal development and F4/80 expression in macrophages. *Mol Cell Biol* 26:5715–5727.
78. Sarrazin S, Mossadegh-Keller N, Fukao T, Aziz A, Mourcin F, Vanhille L, Kelly Modis L, Kastner P, Chan S, Duprez E, Otto C, Sieweke MH. 2009. MafB restricts M-CSF-dependent myeloid commitment divisions of hematopoietic stem cells. *Cell* 138:300–313.
79. Hume DA. 2008. Macrophages as APC and the dendritic cell myth. *J Immunol* 181:5829–5835.
80. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ. 2010. Unravelling mononuclear phagocyte heterogeneity. *Nat Rev Immunol* 10:453–460.
81. Hume DA, Mabbott N, Raza S, Freeman TC. 2013. Can DCs be distinguished from macrophages by molecular signatures? *Nat Immunol* 14:187–189.
82. Mildner A, Jung S. 2014. Development and function of dendritic cell subsets. *Immunity* 40:642–656.
83. Gautier EL, Shay T, Miller J, Greter M, Jakubczik C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, Mazloom AR, Ma'ayan A, Chua WJ, Hansen TH, Turley SJ, Merad M, Randolph GJ, Immunological Genome Consortium. 2012. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. *Nat Immunol* 13:1118–1128.
84. Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, Pandey G, Leboeuf M, Elpek KG, Helft J, Hashimoto D, Chow A, Price J, Greter M, Bogunovic M, Bellemare-Pelletier A, Frenette PS, Randolph GJ, Turley SJ, Merad M, Immunological Genome Consortium. 2012. Deciphering the transcriptional network of the dendritic cell lineage. *Nat Immunol* 13:888–899.
85. Doig TN, Hume DA, Theodoridis T, Goodlad JR, Gregory CD, Freeman TC. 2013. Coexpression analysis of large cancer datasets provides insight into the cellular phenotypes of the tumour microenvironment. *BMC Genomics* 14:469. doi:10.1186/1471-2164-14-469.
86. Vu Manh TP, Bertho N, Hosmalin A, Schwartz-Cornil I, Dalod M. 2015. Investigating evolutionary conservation of dendritic cell subset identity and functions. *Front Immunol* 6:260. doi:10.3389/fimmu.2015.00260.
87. Merad M, Sathe P, Helft J, Miller J, Mortha A. 2013. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. *Annu Rev Immunol* 31:563–604.
88. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB, GenISIS Investigators, MOSAIC Investigators, Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P. 2012. IFITM3 restricts the morbidity and mortality associated with influenza. *Nature* 484:519–523.
89. Haegel H, Thioudellet C, Hallet R, Geist M, Menguy T, Le Pogam F, Marchand JB, Toh ML, Duong V, Calcei A, Settelen N, Preville X, Hennequi M, Grellier B, Ancian P, Rissanen J, Clayette P, Guillen C, Rooke R, Bonnefoy JY. 2013. A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells. *MAbs* 5:736–747.
90. Malissen B, Tamoutounour S, Henri S. 2014. The origins and functions of dendritic cells and macrophages in the skin. *Nat Rev Immunol* 14:417–428.
91. Tamoutounour S, Williams M, Montanana Sanchis F, Liu H, Terhorst D, Malosse C, Pollet E, Ardouin L, Luche H, Sanchez C, Dalod M, Malissen B, Henri S. 2013. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. *Immunity* 39:925–938.
92. Williams M, Ginhoux F, Jakubczik C, Naik SH, Onai N, Schraml BU, Segura E, Tussiwand R, Yona S. 2014. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. *Nat Rev Immunol* 14:571–578.
93. Raza S, Barnett MW, Barnett-Itzhaki Z, Amit I, Hume DA, Freeman TC. 2014. Analysis of the transcriptional networks underpinning the activation of murine macrophages by inflammatory mediators. *J Leukoc Biol* 96:167–183.
94. Sans-Fons MG, Yeramian A, Pereira-Lopes S, Santamaria-Babi LF, Modolell M, Lloberas J, Celada A. 2013. Arginine transport is impaired in C57Bl/6 mouse macrophages as a result of a deletion in the promoter of *Slc7a2* (CAT2), and susceptibility to *Leishmania* infection is reduced. *J Infect Dis* 207:1684–1693.
95. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL. 2014. Identification of a unique TGF- $\beta$ -dependent molecular and functional signature in microglia. *Nat Neurosci* 17:131–143.
96. Schilling E, El Chartouni C, Rehli M. 2009. Allele-specific DNA methylation in mouse strains is mainly determined by *cis*-acting sequences. *Genome Res* 19:2028–2035.
97. Heinz S, Romanoski CE, Benner C, Allison KA, Kaikkonen MU, Orozco LD, Glass CK. 2013. Effect of natural genetic variation on enhancer selection and function. *Nature* 503:487–492.
98. Wells CA, Ravasi T, Faulkner GJ, Carninci P, Okazaki Y, Hayashizaki Y, Sweet M, Wainwright BJ, Hume DA. 2003. Genetic control of the innate immune response. *BMC Immunol* 4:5. doi:10.1186/1471-2172-4-5.
99. Chen L, Kostadima M, Martens JH, Canu G, Garcia SP, Turro E, Downes K, Macaulay IC, Bielczyk-Maczynska E, Coe S, Farrow S, Poudel P, Burden F, Jansen SB, Astle WJ, Attwood A, Bariana T, de Bono B, Breschi A, Chambers JC, BRIDGE Consortium, Choudry FA, Clarke L, Coupland P, van der Ent M, Erber WN, Jansen JH, Favier R, Fenech ME, Foad N, Freson K, van Geet C, Gomez K, Guigo R, Hampshire D, Kelly AM, Kerstens HH, Kooner JS, Laffan M, Lentaigne C, Labalette C, Martin T, Meacham S, Mumford A, Nürnberg S, Palumbo E, van der Reijden BA, Richardson D, Sammut SJ, Slodkiewicz G, Tamuri AU, Vasquez L, Voss K, Watt S, Westbury S, Flicek P, Loos R, Goldman N, Bertone P, Read RJ, Richardson S, Cvejic A, Soranzo N, Ouwehand WH, Stunnenberg HG, Frontini M, Rendon A. 2014. Transcriptional diversity during lineage commitment of human blood progenitors. *Science* 345:1251033. doi:10.1126/science.1251033.
100. Laurenti E, Doulatov S, Zandi S, Plumb I, Chen J, April C, Fan JB, Dick JE. 2013. The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment. *Nat Immunol* 14:756–763.
101. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, McConkey ME, Habib N, Yosef N, Chang CY, Shay T, Frampton GM, Drake AC, Leskov I, Nilsson B, Preffer F, Dombkowski D, Evans JW, Liefeld T, Smutko JS, Chen J, Friedman N, Young RA, Golub TR, Regav A, Ebert BL. 2011. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. *Cell* 144:296–309.
102. Qiao W, Wang W, Laurenti E, Turinsky AL, Wodak SJ, Bader GD, Dick JE, Zandstra PW. 2014. Intercellular network structure and regulatory motifs in the human hematopoietic system. *Mol Syst Biol* 10:741. doi:10.15252/msb.20145141.
103. Martinez FO, Gordon S, Locati M, Mantovani A. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. *J Immunol* 177:7303–7311.
104. Pham TH, Benner C, Lichtinger M, Schwarzfischer L, Hu Y, Andreesen R, Chen W, Rehli M. 2012. Dynamic epigenetic enhancer signatures reveal key transcription factors associated with monocytic differentiation states. *Blood* 119:e161–e171. doi:10.1182/blood-2012-01-402453.
105. FANTOM Consortium, Suzuki H, Forrest AR, van Nimwegen E, Daub CO, Balwierz PJ, Irvine KM, Lassmann T, Ravasi T, Hasegawa Y,



- de Hoon MJ, Katayama S, Schroder K, Carninci P, Tomaru Y, Kanamori-Katayama M, Kubosaki A, Akalin A, Ando Y, Arner E, Asada M, Asahara H, Bailey T, Bajic VB, Bauer D, Beckhouse AG, Bertin N, Björkregren J, Brombacher F, Bulger E, Chalk AM, Chiba J, Cloonan N, Dawe A, Dostie J, Engström PG, Essack M, Faulkner GJ, Fink JL, Fredman D, Fujimori K, Furuno M, Gojobori T, Gough J, Grimmond SM, Gustafsson M, Hashimoto M, Hashimoto T, Hatakeyama M, Heinzl S, et al. 2009. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. *Nat Genet* 41:553–562.
106. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, Chen Y, Zhao X, Schmid C, Suzuki T, Ntini E, Arner E, Valen E, Li K, Schwarzfischer L, Glatz D, Raithel J, Lilje B, Rapin N, Bagger FO, Jørgensen M, Andersen PR, Bertin N, Rackham O, Burroughs AM, Baillie JK, Ishizu Y, Shimizu Y, Furuhashi E, Maeda S, Negishi Y, Mungall CJ, Meehan TF, Lassmann T, Itoh M, Kawaji H, Kondo N, Kawai J, Lennartsson A, Daub CO, Heutink P, Hume DA, Jensen TH, Suzuki H, Hayashizaki Y, Müller F, FANTOM Consortium, Forrest AR, Carninci P, Rehli M, Sandelin A. 2014. An atlas of active enhancers across human cell types and tissues. *Nature* 507:455–461.
107. FANTOM Consortium and the RIKEN PMI and CLST (DGT), Forrest AR, Kawaji H, Rehli M, Baillie JK, de Hoon MJ, Haberle V, Lassmann T, Kulakovskiy IV, Lizio M, Itoh M, Andersson R, Mungall CJ, Meehan TF, Schmeier S, Bertin N, Jørgensen M, Dimont E, Arner E, Schmid C, Schaefer U, Medvedeva YA, Plessy C, Vitezic M, Severin J, Semple C, Ishizu Y, Young RS, Francescato M, Alam I, Albanese D, Altschuler GM, Arakawa T, Archer JA, Arner P, Babina M, Rennie S, Balwierz PJ, Beckhouse AG, Pradhan-Bhatt S, Blake JA, Blumenthal A, Bodega B, Bonetti A, Briggs J, Brombacher F, Burroughs AM, Califano A, Cannistraci CV, Carbajo D, et al. 2014. A promoter-level mammalian expression atlas. *Nature* 507:462–470.
108. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirofeh A, Matarese F, Cheng SC, Ratter J, Berentsen K, van der Ent MA, Sharifi N, Janssen-Megens EM, Ter Huurne M, Mandoli A, van Schaik T, Ng A, Burden F, Downes K, Frontini M, Kumar V, Giamarellos-Bourboulis EJ, Ouwehand WH, van der Meer JW, Joosten LA, Wijmenga C, Martens JH, Xavier RJ, Logie C, Netea MG, Stunnenberg HG. 2014. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. *Science* 345:1251086. doi:10.1126/science.1251086.
109. Joshi A, Pooley C, Freeman TC, Lennartsson A, Babina M, Schmidl C, Geijtenbeek T, the FANTOM Consortium, Michael T, Severin J, Itoh M, Lassmann T, Kawaji H, Hayashizaki Y, Carninci P, Forrest AR, Rehli M, Hume DA. 2015. Transcription factor, promoter, and enhancer utilization in human myeloid cells. *J Leukoc Biol* doi:10.1189/jlb.6TA1014-477RR.
110. D'Aveni M, Rossignol J, Coman T, Sivakumaran S, Henderson S, Manzo T, Santos e Sousa P, Bruneau J, Fouquet G, Zavala F, Alegria-Prévot O, Garfa-Traoré M, Suarez F, Trebeden-Nègre H, Mohty M, Bennett CL, Chakraverty R, Hermine O, Rubio MT. 2015. G-CSF mobilizes CD34<sup>+</sup> regulatory monocytes that inhibit graft-versus-host disease. *Sci Transl Med* 7:281ra42. doi:10.1126/scitranslmed.3010435.
111. Schmidl C, Renner K, Peter K, Eder R, Lassmann T, Balwierz PJ, Itoh M, Nagao-Sato S, Kawaji H, Carninci P, Suzuki H, Hayashizaki Y, Andreesen R, Hume DA, Hoffmann P, Forrest AR, Kreutz MP, Edinger M, Rehli M, FANTOM consortium. 2014. Transcription and enhancer profiling in human monocyte subsets. *Blood* 123:e90–e99. doi:10.1182/blood-2013-02-484188.
112. Huber R, Pietsch D, Günther J, Welz B, Vogt N, Brand K. 2014. Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks. *Cell Mol Life Sci* 71:63–92.
113. Carlin LM, Stamatiades EG, Auffray C, Hanna RN, Glover L, Vizcay-Barrera G, Hedrick CC, Cook HT, Diebold S, Geissmann F. 2013. *Nr4a1*-dependent Ly6C<sup>low</sup> monocytes monitor endothelial cells and orchestrate their disposal. *Cell* 153:362–375.
114. Tagoh H, Himes R, Clarke D, Leenen PJ, Riggs AD, Hume D, Bonifer C. 2002. Transcription factor complex formation and chromatin fine structure alterations at the murine *c-fms* (CSF-1 receptor) locus during maturation of myeloid precursor cells. *Genes Dev* 16:1721–1737.
115. Mossadegh-Keller N, Sarrazin S, Kandalla PK, Espinosa L, Stanley ER, Nutt SL, Moore J, Sieweke MH. 2013. M-CSF instructs myeloid lineage fate in single haematopoietic stem cells. *Nature* 497:239–243.
116. Kryszinska H, Hoogenkamp M, Ingram R, Wilson N, Tagoh H, Laslo P, Singh H, Bonifer C. 2007. A two-step, PU.1-dependent mechanism for developmentally regulated chromatin remodeling and transcription of the *c-fms* gene. *Mol Cell Biol* 27:878–887.
117. Ross IL, Dunn TL, Yue X, Roy S, Barnett CJ, Hume DA. 1994. Comparison of the expression and function of the transcription factor PU.1 (Spi-1 proto-oncogene) between murine macrophages and B lymphocytes. *Oncogene* 9:121–132.
118. Reddy MA, Yang BS, Yue X, Barnett CJ, Ross IL, Sweet MJ, Hume DA, Ostrowski MC. 1994. Opposing actions of *c-ets*/PU.1 and *c-myb* protooncogene products in regulating the macrophage-specific promoters of the human and mouse colony-stimulating factor-1 receptor (*c-fms*) genes. *J Exp Med* 180:2309–2319.
119. Bonifer C, Hume DA. 2008. The transcriptional regulation of the colony-stimulating factor 1 receptor (*csf1r*) gene during hematopoiesis. *Front Biosci* 13:549–560.
120. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. 2010. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* 38:576–589.
121. Ross IL, Yue X, Ostrowski MC, Hume DA. 1998. Interaction between PU.1 and another Ets family transcription factor promotes macrophage-specific basal transcription initiation. *J Biol Chem* 273:6662–6669.
122. Hume DA, Sasmono T, Himes SR, Sharma SM, Bronisz A, Constantin M, Ostrowski MC, Ross IL. 2008. The Ewing sarcoma protein (EWS) binds directly to the proximal elements of the macrophage-specific promoter of the CSF-1 receptor (*csf1r*) gene. *J Immunol* 180:6733–6742.
123. Sasmono RT, Oceandy D, Pollard JW, Tong W, Pavli P, Wainwright BJ, Ostrowski MC, Himes SR, Hume DA. 2003. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. *Blood* 101:1155–1163.
124. Sauter KA, Bouhlel MA, O'Neal J, Sester DP, Tagoh H, Ingram RM, Pridans C, Bonifer C, Hume DA. 2013. The function of the conserved regulatory element within the second intron of the mammalian *Csf1r* locus. *PLoS One* 8:e54935. doi:10.1371/journal.pone.0054935.
125. Alder JK, Georgantas RW, III, Hildreth RL, Kaplan IM, Morisot S, Yu X, McDevitt M, Civin CI. 2008. Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo. *J Immunol* 180:5645–5652.
126. Sauter KA, Pridans C, Sehgal A, Tsai YT, Bradford BM, Raza S, Moffat L, Gow DJ, Beard PM, Mabbott NA, Smith LB, Hume DA. 2014. Pleiotropic effects of extended blockade of CSF1R signaling in adult mice. *J Leukoc Biol* 96:265–274.
127. Deng L, Zhou JF, Sellers RS, Li JF, Nguyen AV, Wang Y, Orlofsky A, Liu Q, Hume DA, Pollard JW, Augenlicht L, Lin EY. 2010. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. *Am J Pathol* 176:952–967.
128. Ovchinnikov DA, DeBats CE, Sester DP, Sweet MJ, Hume DA. 2010. A conserved distal segment of the mouse CSF-1 receptor promoter is required for maximal expression of a reporter gene in macrophages and osteoclasts of transgenic mice. *J Leukoc Biol* 87:815–822.
129. Ovchinnikov DA, van Zuylen WJ, DeBats CE, Alexander KA, Kellie S, Hume DA. 2008. Expression of Gal4-dependent transgenes in cells of the mononuclear phagocyte system labeled with enhanced cyan fluorescent protein using *Csf1r*-Gal4VP16/UAS-ECFP double-transgenic mice. *J Leukoc Biol* 83:430–433.

130. van Zuylen WJ, Garceau V, Idris A, Schroder K, Irvine KM, Lattin JE, Ovchinnikov DA, Perkins AC, Cook AD, Hamilton JA, Hertzog PJ, Stacey KJ, Kellie S, Hume DA, Sweet MJ. 2011. Macrophage activation and differentiation signals regulate Schlafen-4 gene expression: evidence for Schlafen-4 as a modulator of myelopoiesis. *PLoS One* 6:e15723. doi:10.1371/journal.pone.0015723.
131. Jacquelin S, Licata F, Dorgham K, Hermand P, Poupel L, Guyon E, Deterre P, Hume DA, Combadière C, Boissonnas A. 2013. CX3CR1 reduces Ly6C<sup>high</sup>-monocyte motility within and release from the bone marrow after chemotherapy in mice. *Blood* 122:674–683.
132. Pridans CE, Lillico S, Whitelaw CBA, Hume DA. 2014. Lentiviral vectors containing mouse Csf1r control elements direct macrophage-restricted expression in multiple species of birds and mammals. *Mol Ther Methods Clin Dev* 1:14010. doi:10.1038/mtm.2014.10.
133. Balic A, Garcia-Morales C, Vervelde L, Gilhooley H, Sherman A, Garceau V, Gutowska MW, Burt DW, Kaiser P, Hume DA, Sang HM. 2014. Visualisation of chicken macrophages using transgenic reporter genes: insights into the development of the avian macrophage lineage. *Development* 141:3255–3265.
134. Cuadros MA, Martin C, Coltey P, Almendros A, Navascués J. 1993. First appearance, distribution, and origin of macrophages in the early development of the avian central nervous system. *J Comp Neurol* 330: 113–129.
135. Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, Amit I. 2014. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell* 159:1312–1326.
136. Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, Stender JD, Chun HB, Garner H, Geissmann F, Glass CK. 2014. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. *Cell* 159:1327–1340.
137. Gautier EL, Ivanov S, Williams JW, Huang SC, Marcelin G, Fairfax K, Wang PL, Francis JS, Leone P, Wilson DB, Artyomov MN, Pearce EJ, Randolph GJ. 2014. Gata6 regulates aspartoacylase expression in resident peritoneal macrophages and controls their survival. *J Exp Med* 211:1525–1531.
138. Rosas M, Davies LC, Giles PJ, Liao CT, Kharfan B, Stone TC, O'Donnell VB, Fraser DJ, Jones SA, Taylor PR. 2014. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. *Science* 344:645–648.
139. Gordon S. 2007. The macrophage: past, present and future. *Eur J Immunol* 37(Suppl 1):S9–S17.
140. Taylor PR, Gordon S. 2003. Monocyte heterogeneity and innate immunity. *Immunity* 19:2–4.
141. Sica A, Mantovani A. 2012. Macrophage plasticity and polarization: in vivo veritas. *J Clin Invest* 122:787–795.
142. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferon- $\gamma$ : an overview of signals, mechanisms and functions. *J Leukoc Biol* 75:163–189.
143. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, MacDonald AS, Allen JE. 2011. Local macrophage proliferation, rather than recruitment from the blood, is a signature of T<sub>H</sub>2 inflammation. *Science* 332:1284–1288.
144. Schroder K, Irvine KM, Taylor MS, Bokil NJ, Le Cao KA, Masterman K-A, Labzin LI, Semple CA, Kapetanovic R, Fairbairn L, Akalin A, Faulkner GJ, Baillie JK, Gongora M, Daub CO, Kawaji H, McLachlan GJ, Goldman N, Grimmond SM, Carninci P, Suzuki H, Hayashizaki Y, Lenhard B, Hume DA, Sweet MJ. 2012. Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. *Proc Natl Acad Sci U S A* 109:E944–E953. doi:10.1073/pnas.1110156109.
145. Kapetanovic R, Fairbairn L, Beraldi D, Sester DP, Archibald AL, Tuggle CK, Hume DA. 2012. Pig bone marrow-derived macrophages resemble human macrophages in their response to bacterial lipopolysaccharide. *J Immunol* 188:3382–3394.
146. Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C, Thomas B, Fabbri M, Crawshaw A, Ho LP, Ten Hacken NH, Cobos Jiménez V, Kootstra NA, Hamann J, Greaves DR, Locati M, Mantovani A, Gordon S. 2013. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. *Blood* 121:e57–e69. doi:10.1182/blood-2012-06-436212.
147. Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol* 8:958–969.
148. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, Ganesan H, Nino-Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, Beyer M, Latz E, Freeman TC, Ulas T, Schultze JL. 2014. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. *Immunity* 40:274–288.
149. Breen FN, Hume DA, Weidemann MJ. 1991. Interactions among granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and IFN- $\gamma$  lead to enhanced proliferation of murine macrophage progenitor cells. *J Immunol* 147:1542–1547.
150. Fairfax BP, Humburg P, Makino S, Naranbhai V, Wong D, Lau E, Jostins L, Plant K, Andrews R, McGee C, Knight JC. 2014. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. *Science* 343:1246949. doi:10.1126/science.1246949.
151. Shalek AK, Satija R, Adiconis X, Gertner RS, Gaublomme JT, Raychowdhury R, Schwartz S, Yosef N, Malboeuf C, Lu D, Trombetta JJ, Gennert D, Gnirke A, Goren A, Hacohen N, Levin JZ, Park H, Regev A. 2013. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. *Nature* 498:236–240.
152. Ravasi T, Wells C, Forest A, Underhill DM, Wainwright BJ, Aderem A, Grimmond S, Hume DA. 2002. Generation of diversity in the innate immune system: macrophage heterogeneity arises from gene-autonomous transcriptional probability of individual inducible genes. *J Immunol* 168:44–50.
153. Pereira JP, Girard R, Chaby R, Cumano A, Vieira P. 2003. Monoallelic expression of the murine gene encoding Toll-like receptor 4. *Nat Immunol* 4:464–470.
154. Kondo T, Kawai T, Akira S. 2012. Dissecting negative regulation of Toll-like receptor signaling. *Trends Immunol* 33:449–458.
155. Wells CA, Ravasi T, Hume DA. 2005. Inflammation suppressor genes: please switch out all the lights. *J Leukoc Biol* 78:9–13.
156. Lee TK, Covert MW. 2010. High-throughput, single-cell NF- $\kappa$ B dynamics. *Curr Opin Genet Dev* 20:677–683.
157. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA. 2014. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* 41:14–20.
158. Robert C, Lu X, Law A, Freeman TC, Hume DA. 2011. Macrophages.com: an on-line community resource for innate immunity research. *Immunobiology* 216:1203–1211.
159. Pham TH, Minderjahn J, Schmid C, Hoffmeister H, Schmidhofer S, Chen W, Längst G, Benner C, Rehli M. 2013. Mechanisms of *in vivo* binding site selection of the hematopoietic master transcription factor PU.1. *Nucleic Acids Res* 41:6391–6402.